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Introduction
Patients with coronavirus disease 2019 (COVID-19) typically 
present with respiratory symptoms, but little is known about 
the disease’s potential neurological complications.
We report a case of Guillain–Barré syndrome (GBS) following a 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection, in association with leptomeningeal enhancement.
Case presentation
A 56-year-old woman presented with recent unsteadiness and 
paraesthesia in both hands. Fifteen days earlier, she complained 
of fever, dry cough and shortness of breath. Her chest X-ray 
showed a lobar consolidation and PCR was positive for SARS-
CoV-2; she was admitted due to mild COVID-19 pneumonia.
In the first 48 hours of hospitalisation, she started to 
experience lumbar pain and weakness of the proximal lower 
extremities, progressing to bilateral facial nerve palsy, 
oropharyngeal weakness and severe proximal tetraparesis 
with cervical flexion 2/5 on the MRC scale. Full spine magnetic 
resonance imaging (MRI) showed a brainstem and cervical 
leptomeningeal enhancement. Analysis of cerebrospinal fluid 
(CSF) revealed albumin–cytological dissociation. Microbiological 
studies on CSF, including SARS-CoV-2, were negative. Nerve 
conduction studies were consistent with demyelinating 
neuropathy. She was treated with intravenous immunoglobulin, 
with significant neurological improvement noted over the next 
2 weeks.
Conclusion
Leptomeningeal enhancement is an atypical feature in GBS, but 
could be a marker of its association with SARS-CoV-2 infection.
KEYWORDS: COVID-19, SARS-CoV-2, Guillain–Barré syndrome, 
leptomeningeal enhancement, coronavirus 
DOI: 10.7861/clinmed.2020-0213
Authors: Aconsultant in neurology, Hospital Universitario Miguel 
Servet, Zaragoza, Spain; Bconsultant in neuroradiology, Hospital 
Universitario Miguel Servet, Zaragoza, Spain; Cconsultant in clinical 
neurophysiology, Hospital Universitario Miguel Servet, Zaragoza, 










The outbreak of coronavirus disease 2019 (COVID-19), originating 
from Wuhan (China), is caused by severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), which is closely related to SARS-CoV-1 
and Middle East respiratory syndrome coronavirus (MERS-CoV). It 
has spread rapidly around the world and has become pandemic. 
Patients’ symptoms typically include non-productive cough, fever, 
fatigue and dyspnoea, causing pneumonia and severe acute 
respiratory syndrome (SARS).1 Although neurological manifestations 
such as hyposmia, dizziness or headache are increasingly 
recognised, there is little literature regarding neuromuscular 
complications.
We report a patient presenting with Guillain–Barré syndrome 
(GBS) following a SARS-CoV-2 respiratory infection.
Case presentation
A 56-year-old woman presented with recent unsteadiness and 
paraesthesia in both hands. Fifteen days earlier, she had reported 
fever, dry cough and shortness of breath that was controlled with 
symptomatic treatment. All relatives with whom she lived had the 
same symptoms, two being positive for SARS-CoV-2 and one of 
them dying due to severe respiratory infection in the weeks before.
Her chest X-ray showed a lobar consolidation, and nasopharyngeal 
swab was positive for SARS-CoV-2 on PCR assay. She started 
treatment with hydroxychloroquine and azithromycin.
In the first 48 hours of hospitalisation, she developed lumbar 
pain and progressive proximal lower limb weakness. Physical 
examination at that time found normal cognition and cranial 
nerve function, but a mild proximal tetraparesis 4/5 on the Medical 
Research Council (MRC) scale with global areflexia. Sensation to 
light touch, pinprick and proprioception were normal. There were 
no problems with sphincter control.
Due to the diagnostic uncertainty, given the limited knowledge 
related to the neurological complications of SARS-CoV-2, we 
requested magnetic resonance imaging (MRI) of her whole spine, 
which showed brainstem and cervical meningeal enhancement 
(Fig 1). Her cerebrospinal fluid (CSF) showed three leukocytes and 
protein of 0.86 g/L. Microbiological studies on CSF, including SARS-
CoV-2, were negative. Antiganglioside antibodies were negative.
We started intravenous immunoglobulin 2 g/kg over 5 days. 
However, her condition progressed in the next 24 hours with 
bilateral facial nerve palsy, oropharyngeal weakness and severe 
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proximal tetraparesis with cervical flexion 2/5 on the MRC scale. 
She was transferred to the intensive care unit for 5 days due to 
the risk of respiratory insufficiency and began rehabilitation, 
not needing mechanical ventilation. She started recovering by 
day 7 after the onset of weakness. On her worst neurological 
examination, she had bilateral facial diplegia, dysphagia, 
tetraparesis 2/5 proximal and 3/5 distal on the MRC scale and 
global areflexia. There was no compromise of eye movements or 
ataxia.
Nerve conduction studies on day 11 showed delayed distal 
latencies and absent F waves, consistent with a demyelinating 
neuropathy. 
Discussion
To date, there have been a very few reported cases of GBS 
associated with COVID-19.2,3 Some of these followed a 
parainfective profile, raising the question of whether this 
association could be coincidental. GBS overlapping with 
Bickerstaff’s brainstem encephalitis (BBE) was reported in 
association with MERS-CoV infection,4 but we have not found 
any case in association with SARS-CoV-1, where neuromuscular 
problems are considered to be, mostly, critical-illness 
polyneuropathy or myopathy.
We report a case of GBS following SARS-CoV-2 infection in a 
postinfective profile as reported in association with other viruses 
such as cytomegalovirus, Epstein–Barr virus, influenza A virus, Zika 
virus or hepatitis E virus.5
Contrast-enhanced MRI of spine is suggested as a supplementary 
diagnostic modality in diagnosing GBS, especially when the clinical 
and electrophysiological findings are equivocal. In this patient, 
the contrast-enhanced T1-weighted sequence suggested a subtle 
anterior cervical and brainstem leptomeningeal enhancement. 
In GBS, enhancement of spinal roots is not uncommon and 
indicates a breakdown of the blood–nerve barrier. However, diffuse 
leptomeningeal enhancement has recently been documented in 
paediatric GBS, spreading from the posterior fossa to the cauda 
equina.6 In a recent report, eight out of 13 SARS-CoV-2 infections with 
unexplained encephalopathy had leptomeningeal enhancement 
without cells in CSF.7
Some authors suggest that coronaviruses may be neurotropic  
and directly infect and damage motor neurons and peripheral 
nerves, as seen in some viral infections such as poliovirus, 
enterovirus D68 or cytomegalovirus.8 However, in this patient, the 
absence of cells and the negativity for SARS-CoV-2 in CSF allowed 
us to rule out this hypothesis.
Overall, this report supports the existence of a causal relationship 
between GBS and SARS-CoV-2 infection in a classic postinfective 
pattern, but more cases are necessary for better understanding of 
this potential association. The meningeal enhancement related to 
SARS-CoV-2 warrants further investigation. 
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Fig 1. T1-weighted sagittal imaging after gadolinium, showing an 
anterior brainstem and cervical leptomeningeal enhancement.
